Nephros, Inc. - Common Stock (NEPH)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — May 11, 2026Investment Snapshot
- Trading 92% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -36.1%
- Revenue growing at 33% annually
Nephros, Inc. - Common Stock (NEPH) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $38 million . Key value metrics: P/E ratio 30.0, P/B ratio 4.15, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Nephros, Inc. - Common Stock — Fundamental Analysis Summary
Nephros, Inc. - Common Stock (NEPH) is currently trading 92% above its Graham Number of $1.83, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 30.0x.
On financial health, NEPH shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -36.1% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.05.
StockPik's composite Value Score for NEPH is 69/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NEPH reports a high gross margin of 61.5% (sector average: 40.1%) and a modest operating margin of 6.4%.
NEPH shows revenue growing at 33% year-over-year, with earnings growing at 1,514%.